Literature DB >> 31602287

Bayesian Approach for Assessing Non-inferiority in Three-arm Trials for Risk Ratio and Odds Ratio.

Shrabanti Chowdhury1,2, Ram C Tiwari3, Samiran Ghosh1,2.   

Abstract

In this paper we consider three-arm non-inferiority (NI) trial that includes an experimental, a reference, and a placebo arm. While for binary outcomes the risk difference (RD) is the most common and well explored functional form for testing efficacy (or effectiveness), recent FDA guideline suggested other measures such as relative risk (RR) and odds ratio (OR) on the basis of which NI of an experimental treatment can be claimed. However, developing test based on these different functions of binary outcomes are challenging since the construction and interpretation of NI margin for such functions are not trivial extensions of RD based approach. Recently, we have proposed Frequentist approaches for testing NI for these functionals. In this article we further develop Bayesian approaches for testing NI based on effect retention approach for RR and OR. Bayesian paradigm provides a natural path to integrate historical trials' information, as well as it allows the usage of patients'/clinicians' opinions as prior information via sequential learning. In addition we discuss, in detail, the sample size/power calculation which could be readily used while designing such trials in practice.

Entities:  

Keywords:  Assay Sensitivity; Binary Outcome; Fraction Margin; Markov chain Monte Carlo; Non-inferiority Margin; Risk/Odds Ratio; Three-arm Trial

Year:  2019        PMID: 31602287      PMCID: PMC6786783          DOI: 10.1080/19466315.2018.1554504

Source DB:  PubMed          Journal:  Stat Biopharm Res        ISSN: 1946-6315            Impact factor:   1.452


  20 in total

1.  Assessing non-inferiority of a new treatment in a three-arm clinical trial including a placebo.

Authors:  Iris Pigeot; Juliane Schäfer; Joachim Röhmel; Dieter Hauschke
Journal:  Stat Med       Date:  2003-03-30       Impact factor: 2.373

2.  Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics.

Authors:  Ralph B D'Agostino; Joseph M Massaro; Lisa M Sullivan
Journal:  Stat Med       Date:  2003-01-30       Impact factor: 2.373

3.  Multiple testing of noninferiority hypotheses in active controlled trials.

Authors:  H M James Hung; Sue-Jane Wang
Journal:  J Biopharm Stat       Date:  2004-05       Impact factor: 1.051

4.  On the three-arm non-inferiority trial including a placebo with a prespecified margin.

Authors:  Eisuke Hida; Toshiro Tango
Journal:  Stat Med       Date:  2010-11-05       Impact factor: 2.373

5.  Planning and analysis of three-arm non-inferiority trials with binary endpoints.

Authors:  Meinhard Kieser; Tim Friede
Journal:  Stat Med       Date:  2007-01-30       Impact factor: 2.373

6.  A mixed approach for proving non-inferiority in clinical trials with binary endpoints.

Authors:  Valentin Rousson; Burkhardt Seifert
Journal:  Biom J       Date:  2008-04       Impact factor: 2.207

7.  Bayesian approach to the design and analysis of non-inferiority trials for anti-infective products.

Authors:  Meg A Gamalo; Ram C Tiwari; Lisa M LaVange
Journal:  Pharm Stat       Date:  2013-08-05       Impact factor: 1.894

8.  Assessing noninferiority in a three-arm trial using the Bayesian approach.

Authors:  Pulak Ghosh; Farouk Nathoo; Mithat Gönen; Ram C Tiwari
Journal:  Stat Med       Date:  2011-04-26       Impact factor: 2.373

9.  Noninferiority trial designs for odds ratios and risk differences.

Authors:  Joan F Hilton
Journal:  Stat Med       Date:  2010-02-26       Impact factor: 2.373

10.  Assessing additional benefit in noninferiority trials.

Authors:  Meinhard Kieser; Kathrin Stucke
Journal:  Biom J       Date:  2014-06-30       Impact factor: 2.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.